New York State Common Retirement Fund’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.7K | Hold |
3,902
| – | – | ﹤0.01% | 3039 |
|
|
2026
Q1 | $24K | Hold |
3,902
| – | – | ﹤0.01% | 2986 |
|
|
2025
Q4 | $28.1K | Hold |
3,902
| – | – | ﹤0.01% | 3037 |
|
|
2025
Q3 | $39.9K | Hold |
3,902
| – | – | ﹤0.01% | 3009 |
|
|
2025
Q2 | $40.5K | Hold |
3,902
| – | – | ﹤0.01% | 2996 |
|
|
2025
Q1 | $51.4K | Hold |
3,902
| – | – | ﹤0.01% | 2762 |
|
|
2024
Q4 | $69.9K | Sell |
3,902
-1,200
| -24% | -$24.3K | ﹤0.01% | 2740 |
|
|
2024
Q3 | $82.2K | Hold |
5,102
| – | – | ﹤0.01% | 2682 |
|
|
2024
Q2 | $138K | Buy |
5,102
+3,598
| +239% | +$85.9K | ﹤0.01% | 2591 |
|
|
2024
Q1 | $29.3K | Hold |
1,504
| – | – | ﹤0.01% | 3095 |
|
|
2023
Q4 | $31.1K | Sell |
1,504
-5
| -0.3% | -$149 | ﹤0.01% | 3097 |
|
|
2023
Q3 | $48K | Sell |
1,509
-1,318
| -47% | -$44K | ﹤0.01% | 3034 |
|
|
2023
Q2 | $95K | Buy |
+2,827
| New | +$101K | ﹤0.01% | 2893 |
|
|
2022
Q3 | – | Sell |
-30
| Closed | -$1K | – | 3421 |
|
|
2022
Q2 | $1K | Sell |
30
-1,697
| -98% | -$50.3K | ﹤0.01% | 3397 |
|
|
2022
Q1 | $64K | Buy |
1,727
+4
| +0.2% | +$250 | ﹤0.01% | 3119 |
|
|
2021
Q4 | $168K | Sell |
1,723
-7
| -0.4% | -$753 | ﹤0.01% | 2933 |
|
|
2021
Q3 | $216K | Sell |
1,730
-839
| -33% | -$101K | ﹤0.01% | 2881 |
|
|
2021
Q2 | $322K | Buy |
2,569
+1,215
| +90% | +$145K | ﹤0.01% | 2813 |
|
|
2021
Q1 | $184K | Buy |
1,354
+411
| +44% | +$51K | ﹤0.01% | 2868 |
|
|
2020
Q4 | $86K | Sell |
943
-1,124
| -54% | -$97.5K | ﹤0.01% | 3089 |
|
|
2020
Q3 | $154K | Hold |
2,067
| – | – | ﹤0.01% | 2760 |
|
|
2020
Q2 | $176K | Buy |
+2,067
| New | +$187K | ﹤0.01% | 2700 |
|
|
2019
Q2 | – | Sell |
-173
| Closed | -$12K | – | 3287 |
|
|
2019
Q1 | $12K | Hold |
173
| – | – | ﹤0.01% | 3146 |
|
|
2018
Q4 | $14K | Sell |
173
-560
| -76% | -$128K | ﹤0.01% | 3168 |
|
|
2018
Q3 | $342K | Hold |
733
| – | – | ﹤0.01% | 2588 |
|
|
2018
Q2 | $292K | Buy |
733
+273
| +59% | +$96.9K | ﹤0.01% | 2696 |
|
|
2018
Q1 | $141K | Hold |
460
| – | – | ﹤0.01% | 2865 |
|
|
2017
Q4 | $135K | Buy |
460
+43
| +10% | +$18.8K | ﹤0.01% | 2909 |
|
|
2017
Q3 | $228K | Hold |
417
| – | – | ﹤0.01% | 2712 |
|
|
2017
Q2 | $248K | Buy |
417
+270
| +184% | +$119K | ﹤0.01% | 2738 |
|
|
2017
Q1 | $63K | Hold |
147
| – | – | ﹤0.01% | 3039 |
|
|
2016
Q4 | $75K | Buy |
+147
| New | +$85.9K | ﹤0.01% | 3011 |
|
Other funds holding RNAC
6CM
New York State Common Retirement Fund's RNAC Position: Q2 2026 in Review
New York State Common Retirement Fund held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 3,902 shares worth $40.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3039.
New York State Common Retirement Fund first reported a position in RNAC in Q4 2016 and has held it in 32 quarters since. The position peaked at $342K in Q3 2018. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- New York State Common Retirement Fund held 3,902 shares of Cartesian Therapeutics worth $40.7K as of Q2 2026.
- New York State Common Retirement Fund left its Cartesian Therapeutics share count unchanged in Q2 2026.
- Cartesian Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #3039 holding.
- New York State Common Retirement Fund first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 32 quarters since.
- New York State Common Retirement Fund's Cartesian Therapeutics position peaked at $342K in Q3 2018.
- 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.